

1

2 Hypertension in pregnancy

3 **The significance of mitochondrial haplogroups in preeclampsia risk**

4 Kristina Wendelboe Olsen (0000-0002-3902-200X)<sup>1</sup>, Paula L. Hedley (0000-0001-5801-960X)<sup>2,3</sup>,  
5 Christian M. Hagen (0000-0002-0513-7722)<sup>2,4</sup>, Line Rode (0000-0002-9080-3389)<sup>5</sup>, Sophie Placing<sup>2</sup>,  
6 Karen R Wøjdemann(0000-0002-6707-1677)<sup>7</sup>, Anne-Cathrine Shalmi<sup>6</sup>, Karin Sundberg(0000-0001-  
7 5598-5773)<sup>8</sup>, Anne Nørremølle (0000-0003-2561-7683)<sup>9</sup>, Ann Tabor (0000-0001-7450-1543)<sup>8,10</sup>,  
8 Joanna L. Elson (0000-0002-3551-5624)<sup>2,11\*</sup> & Michael Christiansen (0000-0003-4713-755X)<sup>2,4</sup>

9 <sup>1</sup>*Fertility Department, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark*

10 <sup>2</sup>*Department for Congenital Disorders, Statens Serum Institut, 2300 Copenhagen, Denmark*

11 <sup>3</sup>*Brazen Bio, Los Angeles, California, USA*

12 <sup>4</sup>*Department of Biomedical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark*

13 <sup>5</sup>*Department of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, 2600 Glostrup*

14 <sup>6</sup>*Department of Obstetrics, Hillerød Sygehus, 3400 Hillerød, Denmark*

15 <sup>7</sup>*Department of Gynecology and Obstetrics, Bornholm Hospital, 3700 Rønne, Bornholm, Denmark*

16 <sup>8</sup>*Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital Rigshospitalet, 2100  
17 Copenhagen, Denmark*

18 <sup>9</sup>*Department of Cellular and Molecular Medicine, University of Copenhagen, Denmark*

19 <sup>10</sup>*Department of Clinical Medicine, Faculty of Medical and Health Sciences, University of Copenhagen, 2200  
20 Copenhagen, Denmark*

21 <sup>11</sup>*Biosciences Institute Newcastle University, Newcastle UK*

22 **Short title:** mtDNA haplogroups in Preeclampsia

23 **Journal:** Hypertension in Pregnancy


24 **Word Count:** 2539 words

25 \*corresponding author

26 Joanna L. Elson, Ph.D

27 Institute of Genetic Medicine  
28 International Centre for Life,  
29 Central Parkway, Newcastle upon Tyne, NE1 3BZ, United Kingdom  
30 E.mail: j.l.elson@ncl.ac.uk

31 **Graphical Abstract** (to be submitted separately)



32

### 33 **The significance of mitochondrial haplogroups in preeclampsia risk**

34 **Objective:** To determine whether mitochondrial haplogroups function as disease-modifiers or as  
35 susceptibility factors in preeclampsia using a traditional haplogroup association model.

36 **Methods:** This retrospective study haplotyped 235 control and 78 preeclamptic pregnancies from  
37 Denmark using either real-time PCR or Sanger sequencing depending on the rarity of the  
38 haplogroup.

39 **Results:** No significant association between haplogroups and the risk of preeclampsia was found,  
40 nor was any role for haplogroups in disease severity uncovered.

41 **Conclusion:** Mitochondrial haplogroups are not associated with preeclampsia or the severity of  
42 preeclampsia in the Danish population. However, this study cannot exclude a role for less  
43 common mtDNA variation. Models that can examine these should be applied in preeclamptic  
44 patients.

45 **Key Words:** pregnancy; preeclampsia; mitochondrial DNA; mitochondrial haplogroups

## 46 **Introduction**

47 Preeclampsia affects 2-7 % of all pregnancies in the western world, and is the greatest cause of  
48 maternal mortality and morbidity worldwide [1-3]. It is a multisystem pregnancy disorder diagnosed by  
49 the presence of hypertension and proteinuria with symptoms varying from mild hypertension,  
50 proteinuria and edema to multi-organ failure [2, 4, 5]. Preeclampsia has a poorly understood etiology,  
51 but it is believed to be influenced by genetic, immunological and environmental factors [6]. Two  
52 clinical syndromes results from preeclampsia; one in the mother and one in the fetus [4]. The maternal  
53 syndrome is characterized by hypertension, frequently proteinuria, or other systemic abnormalities. In  
54 the United Kingdom the main cause of maternal mortality among preeclampsia cases is pulmonary  
55 edema [7]. PE is associated with metabolic, cardiac and other disorders later in life for both mother and  
56 child [5].

57 By definition preeclampsia develops after the 20th week and can be classified as early-onset or  
58 late-onset; before or after the 34th week of gestation [8]; it can occur with or without intrauterine  
59 growth restriction [9] and has been associated with respiratory distress in very low birth weight  
60 infants [10]. The risk for adverse neonatal outcome is increased with early-onset preeclampsia [6],  
61 which, together with restricted fetal growth is associated with high incidence of stillbirth and perinatal  
62 death [11]. Preeclampsia can be divided into two-stage disease: Stage I, the asymptomatic stage with  
63 abnormal placentation, and stage II, during which clinical signs and symptoms develop [12, 13].  
64 Preeclampsia is the result of changes initiated in the first trimester of pregnancy [14]. Preventative  
65 treatment, with low dose aspirin, started late in the first trimester, has been recommended for high-risk  
66 pregnancies [15]. However, the risk of developing preeclampsia is typically – and increasingly -  
67 assessed using either demographic variables or clinical history and or biomarkers [16-18].

68 In healthy pregnancies the placentation begins with the blastocysts adhering to the uterine  
69 endometrium (decidua) and forming invasive extravillous cytotrophoblast cells. These cells invade the  
70 uterine wall by changing their phenotype from epithelia to endothelia to create vessels for the placental  
71 circulation. The predominant theory of the pathogenesis of preeclampsia is that the cytotrophoblasts  
72 fail to switch their phenotype, which leads to small, poorly developed spiral arteries resulting in a  
73 compromised maternal-fetal blood flow [19]. Persistent defective placental perfusion produces  
74 placental hypoxia which will subsequently lead to oxidative stress [20, 21]. Oxidative stress has been  
75 shown to be present in placental tissue, moreover there is a higher level of oxidative stress in  
76 preeclampsia and other pregnancy-related pathologies [22, 23], indeed, higher levels of oxidative stress  
77 have been shown to be present prior to the diagnosis of PE [24]. Furthermore, aberrant placental energy  
78 metabolism may explain some of the signs and symptoms of preeclampsia [25], and mitochondrial  
79 proteins have also been associated with apoptosis, oxidative stress, reactive oxygen species (ROS)  
80 generation and mitochondrial damage [26]. This suggests that mitochondria play a role in the  
81 development of preeclampsia.

82 The mitochondria are responsible for producing the majority of cellular ATP by oxidative  
83 phosphorylation which also produces ROS such as superoxide ( $O_2^-$ ) and hydrogen peroxide ( $H_2O_2$ ). It  
84 has been assumed that these ROS are continually generated as a result of mitochondrial respiration and  
85 are key to some disease processes as well as ageing [27]. Our understanding of ROS has increased in  
86 recent years following the elucidation of their role as signaling molecules [28]. The presence of  
87 mitochondrial DNA (mtDNA), the mitochondria's own genetic material, is unique among cellular  
88 organelles. This circular, double stranded molecule encompasses ~16 kbp of DNA in humans [29]. It  
89 codes for 13 polypeptides of the mitochondrial respiratory chain, two ribosomal RNAs and the 22  
90 transfer RNAs necessary for the mitochondrial protein synthesis in the matrix. All other mitochondrial

91 proteins are encoded by nuclear genes. Each mammalian cell contains several hundreds or thousands of  
92 mitochondria depending on the cell's energy demands [30]. MtDNA is maternally inherited which  
93 means the evolution of mtDNA is defined by the emergence of distinct lineages called  
94 haplogroups [31]. Variation in mtDNA has been linked to a number of complex traits [32, 33] and it  
95 has been suggested that this might be linked to differential mitochondrial performance but this is a  
96 controversial field [34].

97 Torbergsen and coworkers were the first to discover a high incidence of preeclampsia in  
98 families with mitochondrial dysfunction [35]; an indication that mitochondria are involved in  
99 preeclampsia [36, 37] and thus potentially mtDNA variation could affect the function of the placenta,  
100 and thereby lead to the development of preeclampsia. The mitochondrial haplogroup H, by far the most  
101 frequent in Denmark [38], has been shown by some to have higher VO<sub>2</sub>max but is also associated with  
102 increased mitochondrial oxidative stress compared to some other haplogroups [39, 40]. These studies  
103 have been supported by more recent work looking at athletic performance [41], and an association to  
104 heart disease [42]. As with many observations in the mitochondrial association field this has been  
105 controversial [43]. However, we hypothesized that, if this were true, haplogroup H will be  
106 overrepresented in first-trimester pregnancies which would go on to develop preeclampsia compared to  
107 non-complicated pregnancies. The idea of comparing haplogroup H to other European groups has been  
108 taken due to the high frequency of haplogroup H in the European population [44].



## 109 **Materials and Methods**

### 110 *Study populations*

111 The study cohort comprised of 78 Danish women with preeclampsia and a control group of 235  
112 pregnant Danish women. The study was a case-control sub study, using patients where dried blood spot  
113 samples were available, of the Copenhagen First Trimester Screening Study (CFTSS) [45]. Several  
114 biomarker studies in PE have been conducted as sub studies of the CFTSS [46-49]. The clinical and  
115 demographical data of participants are given in table 1. General population control data were obtained  
116 from the Copenhagen City Heart Study (Østerbroundersøgelsen) [50], where the haplotyping is based  
117 on haplogroup specific markers in the hypervariable regions (HV1 and HV2) of the mtDNA.

118 In this study, preeclampsia was defined according to the guidelines of the Danish Society for  
119 Obstetrics and Gynecology ([www.dsog.dk](http://www.dsog.dk))[51], except that proteinuria was required. The maternal  
120 systolic blood pressure should be more than 140 mmHg and diastolic blood pressure more than 90 mm  
121 Hg, along with  $\geq 0.3$  g protein in a urine specimen after 20 weeks of gestation in women with  
122 previously normal blood pressure. Severe PE had BP > 160 mm Hg (sys) and/or 110 mm Hg(dia)  
123 and/or severe organ involvement, as defined in the guidelines[51]. HELLP syndrome required  
124 laboratory signs of hemolysis, ALAT/ASAT > 70 U/L, and less than  $10^9$  platelets per L [51].

### 125 *Haplotyping of mtDNA*

126 For the determination of mitochondrial haplogroup all 78 patients and 235 controls were haplotyped.  
127 Most of them were haplotyped using TaqMan real time PCR [52], while individuals with an  
128 uncommon haplogroup were examined with Sanger Sequencing.



129 *Statistics*

130 Frequencies of all mitochondrial haplogroups in preeclamptic patients and controls were tested for  
131 independence using Fisher's exact test as appropriate. Similarly, frequencies of mitochondrial  
132 haplogroups were compared between controls from a general population study and pregnancy controls.  
133 Odds-ratios and 95% confidence intervals were calculated.

134 *Ethics statement*

135 The Copenhagen First Trimester Screening Study was conducted according to the guidelines of the  
136 Declaration of Helsinki and approved by the Scientific ethics committee of the cities of Copenhagen  
137 and Frederiksberg (No. (KF) 01-288/97) and the Data protection Agency[[45](#)].

138 **Results**

139 *Haplogroup distribution*

140 The distribution of haplogroups in preeclamptic pregnancies as well as control pregnancies and in a  
141 Danish population control group [45, 50] is given in table 2. These results were obtained from the  
142 TaqMan real time PCR and the Sanger Sequencing.

143 *Validation of pregnancy controls*

144 To investigate whether or not the pregnancy controls from CFTSS are representative for the Danish  
145 population, Fishers exact test was performed to compare them with the haplogroup distribution in a  
146 general Danish population [45], table 3. It shows that there were no significant differences, therefore, it  
147 can be concluded that the pregnancy control group is representative for the general Danish population.

148 *Haplogroup distribution and preeclampsia and severity of preeclampsia*

149 The data did not support a link between European haplogroups and PE, table 4. None of the  
150 uncorrected p-values indicate significance when comparing the control pregnancies with the PE  
151 pregnancies, with the value for the most common of the European haplogroups H being  $p=0.55$ . Note  
152 that there was no difference when the PE pregnancies were compared to the general Danish population.

153 The PE cases were divided into mild (PE 1), severe (PE 2), and HELLP cases (PE 3), Table 1.

154 The distribution of clinical severity as a function of mtDNA haplogroups is depicted in Figure 1. No  
155 difference was seen; however, the statistical power is very limited.

156 **Discussion**

157 Several health and disease states have been found to be associated with the different mitochondrial  
158 haplogroups [33, 42]. In this study the association between the mitochondrial haplogroups and the  
159 development of preeclampsia was studied in an attempt to determine if mitochondrial haplogroups  
160 function as disease-modifiers or as susceptibility factors in preeclampsia using a traditional haplogroup  
161 association model.

162 The placenta plays an important role in development of preeclampsia [19, 36]. As mitochondria  
163 are maternally inherited [53], the fetus, the placenta and the mother have the same mitochondrial  
164 haplogroup; consequently, the placental mtDNA haplogroup can be determined from a blood sample  
165 from either the mother or – in retrospective studies – from the child.

166 Blood and clinical data from 78 patients with preeclampsia and 235 healthy pregnancy controls  
167 were employed to investigate the possibility that preeclampsia is associated with haplogroup H as such  
168 an association has been demonstrated in Danish hypertrophic cardiomyopathy patients [42]. Since  
169 haplogroup H exhibits increased ROS production, oxidative damage and higher VO<sub>2</sub>max [39, 40] the  
170 preeclamptic women are hypothesized to be more likely to have haplogroup H compared to the controls  
171 due to the association between preeclampsia and oxidative stress [21, 24].

172 The CFTSS pregnancy controls were validated by comparing them with the haplogroup  
173 distribution from a Danish general population study. This comparison showed no significant  
174 differences (p-value between 0.13-0.79 in a Fisher's exact test), thus the controls fit the distribution  
175 seen in the general population, table 2. The haplogroup distribution of preeclamptic patients and  
176 healthy controls was compared with Fisher's exact test. No significant difference in the haplogroup  
177 distribution between the different groups (P = 0.98) was found, table 3. When haplogroup H was

178 compared with non-H haplogroups there was likewise no significant difference ( $P = 0.60$ ). The same is  
179 true for the other haplogroups with p-values  $> 0.05$ , table 3.

180 It has also been suggested that mtDNA haplogroups might affect the course of disease [54]. The  
181 severity of preeclampsia might be associated with different haplogroups. With more cases of severe  
182 preeclampsia, it is possible that mitochondrial haplogroups could be proven to predict the  
183 severity/phenotype of the disease. The same might be true for early-onset versus late-onset  
184 preeclampsia, since many researchers suggest that they follow two separate pathogenic pathways [55,  
185 56], they might also be associated with different mitochondrial haplogroups. However, our data on  
186 severity does not support that this should be the case. And the use of a small number of patients makes  
187 the time of birth largely determined by clinical assessment and not biology. It can be difficult to collect  
188 data from severe preeclamptic patients, since almost all women in Denmark make use of the offer of  
189 free medical care and therefore are often treated before the disease develops to more severe stages.  
190 Thus, there might be an undetected association.

191 Haplogroup H was not found to be associated with preeclampsia, but that does not exclude an  
192 association with some of the other haplogroups instead. Because haplogroup J, U, T and K function as  
193 disease-modifiers in other diseases they could be the new association candidates. However, to get  
194 enough statistical power a larger cohort will be needed or another population with a different  
195 haplogroup distribution; a population with high proportion of J, U, T or K. In larger association studies  
196 involving rarer mtDNA variants or rare haplogroups it will, however, be very important to account for  
197 nuclear genomic differences [57].

198 The placental mtDNA content (mtDNA copy number) has shown to be a molecular marker of  
199 mitochondrial damage and mitochondrial inflammation [58]. Exposure to particulate matter in third  
200 trimester has been shown to be associated with mitochondrial damage exemplified by a lower mtDNA

201 content [\[58\]](#). A significant decrease in mtDNA content is also observed in placenta from smokers  
202 compared with non-smokers [\[59\]](#). Since environmental factors show this impact on mitochondria, it  
203 might be that the same can be seen in preeclampsia, only with lower mtDNA content already in the first  
204 trimester where the placenta is poorly implanted. The dysfunctional placental mitochondria in  
205 preeclampsia might be due to a small copy number of mtDNA in the first trimester of pregnancy [\[60,](#)  
206 [61\]](#).

207 **Conclusion**

208 A significant association between mtDNA haplogroups and the risk of preeclampsia was not  
209 demonstrated. However, the diversity of the haplogroups found makes it possible that haplogroups with  
210 low prevalence may actually play a role for occurrence or clinical presentation of PE. There is currently  
211 no basis for considering mtDNA haplogroups potential first trimester risk markers of PE.

212 **Acknowledgements**

213 We would like to acknowledge the technical assistance of Dennis Jelsbak Schmidt. This research has  
214 been conducted using the Danish National Biobank resource, supported by the Novo Nordisk  
215 Foundation.

216

## 217 **References**

- 218 1. Lisonkova S, Sabr Y, Mayer C, Young C, Skoll A, Joseph KS. Maternal morbidity associated with early-  
219 onset and late-onset preeclampsia. *Obstetrics and gynecology*. 2014;124(4):771-81. Epub 2014/09/10. doi:  
220 10.1097/AOG.0000000000000472. PubMed PMID: 25198279.
- 221 2. Duley L. The global impact of pre-eclampsia and eclampsia. *Semin Perinatol*. 2009;33(3):130-7. Epub  
222 2009/05/26. doi: 10.1053/j.semperi.2009.02.010. PubMed PMID: 19464502.
- 223 3. Moodley J, Soma-Pillay P, Buchmann E, Pattinson RC. Hypertensive disorders in pregnancy: 2019  
224 National guideline. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde*.  
225 2019;109(9):12723. Epub 2019/10/23. PubMed PMID: 31635598.
- 226 4. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. *Lancet (London, England)*.  
227 2010;376(9741):631-44. Epub 2010/07/06. doi: 10.1016/S0140-6736(10)60279-6. PubMed PMID: 20598363.
- 228 5. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. *Lancet (London, England)*.  
229 2021;398(10297):341-54. Epub 2021/05/31. doi: 10.1016/S0140-6736(20)32335-7. PubMed PMID: 34051884.
- 230 6. Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on  
231 female reproduction: a review. *Reproductive biology and endocrinology : RB&E*. 2012;10:49. Epub 2012/07/04.  
232 doi: 10.1186/1477-7827-10-49. PubMed PMID: 22748101; PubMed Central PMCID: PMC3527168.
- 233 7. Walker JJ. Pre-eclampsia. *Lancet (London, England)*. 2000;356(9237):1260-5. Epub 2000/11/10. doi:  
234 10.1016/S0140-6736(00)02800-2. PubMed PMID: 11072961.
- 235 8. Audibert F, Boucoiran I, An N, Aleksandrov N, Delvin E, Bujold E, et al. Screening for preeclampsia using  
236 first-trimester serum markers and uterine artery Doppler in nulliparous women. *American journal of obstetrics  
237 and gynecology*. 2010;203(4):383 e1-8. Epub 2010/08/10. doi: 10.1016/j.ajog.2010.06.014. PubMed PMID:  
238 20691410.
- 239 9. Milosevic-Stevanovic J, Krstic M, Radovic-Janosevic D, Stefanovic M, Antic V, Djordjevic I. Preeclampsia  
240 with and without intrauterine growth restriction-Two pathogenetically different entities? *Hypertens  
241 Pregnancy*. 2016;35(4):573-82. Epub 2016/11/03. doi: 10.1080/10641955.2016.1212872. PubMed PMID:  
242 27624400.
- 243 10. Wen YH, Yang HI, Chou HC, Chen CY, Hsieh WS, Tsou KI, et al. Association of Maternal Preeclampsia  
244 with Neonatal Respiratory Distress Syndrome in Very-Low-Birth-Weight Infants. *Sci Rep*. 2019;9(1):13212. Epub  
245 2019/09/15. doi: 10.1038/s41598-019-49561-8. PubMed PMID: 31519996; PubMed Central PMCID:  
246 PMC6744454.
- 247 11. Weiler J, Tong S, Palmer KR. Is fetal growth restriction associated with a more severe maternal  
248 phenotype in the setting of early onset pre-eclampsia? A retrospective study. *PloS one*. 2011;6(10):e26937.  
249 Epub 2011/11/03. doi: 10.1371/journal.pone.0026937. PubMed PMID: 22046419; PubMed Central PMCID:  
250 PMC3203930.
- 251 12. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. *Placenta*.  
252 2009;30 Suppl A:S32-7. Epub 2008/12/17. doi: 10.1016/j.placenta.2008.11.009. PubMed PMID: 19070896;  
253 PubMed Central PMCID: PMC2680383.
- 254 13. Wu P, Haththotuwa R, Kwok CS, Babu A, Kotronias RA, Rushton C, et al. Preeclampsia and Future  
255 Cardiovascular Health: A Systematic Review and Meta-Analysis. *Circ Cardiovasc Qual Outcomes*. 2017;10(2).  
256 Epub 2017/02/24. doi: 10.1161/CIRCOUTCOMES.116.003497. PubMed PMID: 28228456.
- 257 14. Burton GJ, Cindrova-Davies T, Yung HW, Jauniaux E. HYPOXIA AND REPRODUCTIVE HEALTH: Oxygen  
258 and development of the human placenta. *Reproduction*. 2021;161(1):F53-F65. Epub 2020/05/22. doi:  
259 10.1530/REP-20-0153. PubMed PMID: 32438347.



- 260 15. Committee on Obstetric P, Medicine. SfM-F. ACOG Committee Opinion No. 743: Low-Dose Aspirin Use  
261 During Pregnancy. *Obstetrics and gynecology*. 2018;132(1):e44-e52. Epub 2018/06/26. doi:  
262 10.1097/AOG.0000000000002708. PubMed PMID: 29939940.
- 263 16. Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, et al. Screening for pre-eclampsia by  
264 maternal factors and biomarkers at 11-13 weeks' gestation. *Ultrasound Obstet Gynecol*. 2018;52(2):186-95.  
265 Epub 20180711. doi: 10.1002/uog.19112. PubMed PMID: 29896812.
- 266 17. Wright D, Tan MY, O'Gorman N, Poon LC, Syngelaki A, Wright A, et al. Predictive performance of the  
267 competing risk model in screening for preeclampsia. *American journal of obstetrics and gynecology*.  
268 2019;220(2):199 e1- e13. Epub 20181114. doi: 10.1016/j.ajog.2018.11.1087. PubMed PMID: 30447210.
- 269 18. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of  
270 controlled studies. *BMJ*. 2005;330(7491):565. Epub 2005/03/04. doi: 10.1136/bmj.38380.674340.E0. PubMed  
271 PMID: 15743856; PubMed Central PMCID: PMCPMC554027.
- 272 19. Siddiqui N, Hladunewich M. Understanding the link between the placenta and future cardiovascular  
273 disease. *Trends in cardiovascular medicine*. 2011;21(7):188-93. Epub 2012/08/08. doi:  
274 10.1016/j.tcm.2012.05.008. PubMed PMID: 22867697.
- 275 20. Valenzuela FJ, Perez-Sepulveda A, Torres MJ, Correa P, Repetto GM, Illanes SE. Pathogenesis of  
276 preeclampsia: the genetic component. *Journal of pregnancy*. 2012;2012:632732. Epub 2011/12/17. doi:  
277 10.1155/2012/632732. PubMed PMID: 22175024; PubMed Central PMCID: PMCPMC3235819.
- 278 21. Abad C, Proverbio T, Pinero S, Botana D, Chiarello DI, Marin R, et al. Preeclampsia, placenta, oxidative  
279 stress, and PMCA. *Hypertens Pregnancy*. 2012;31(4):427-41. Epub 2012/06/09. doi:  
280 10.3109/10641955.2012.690058. PubMed PMID: 22676487.
- 281 22. Mannaerts D, Faes E, Cos P, Briede JJ, Gyselaers W, Cornette J, et al. Oxidative stress in healthy  
282 pregnancy and preeclampsia is linked to chronic inflammation, iron status and vascular function. *PloS one*.  
283 2018;13(9):e0202919. Epub 2018/09/12. doi: 10.1371/journal.pone.0202919. PubMed PMID: 30204759;  
284 PubMed Central PMCID: PMCPMC6133366.
- 285 23. Gupta S, Aziz N, Sekhon L, Agarwal R, Mansour G, Li J, et al. Lipid peroxidation and antioxidant status in  
286 preeclampsia: a systematic review. *Obstetrical & gynecological survey*. 2009;64(11):750-9. Epub 2009/10/24.  
287 doi: 10.1097/OGX.0b013e3181bea0ac. PubMed PMID: 19849867.
- 288 24. Ahmad IM, Zimmerman MC, Moore TA. Oxidative stress in early pregnancy and the risk of  
289 preeclampsia. *Pregnancy hypertension*. 2019;18:99-102. Epub 2019/10/07. doi: 10.1016/j.pregphy.2019.09.014.  
290 PubMed PMID: 31586785; PubMed Central PMCID: PMCPMC6941664.
- 291 25. Aye I, Aiken CE, Charnock-Jones DS, Smith GCS. Placental energy metabolism in health and disease-  
292 significance of development and implications for preeclampsia. *American journal of obstetrics and gynecology*.  
293 2022;226(2S):S928-S44. Epub 20201113. doi: 10.1016/j.ajog.2020.11.005. PubMed PMID: 33189710.
- 294 26. Shi Z, Long W, Zhao C, Guo X, Shen R, Ding H. Comparative proteomics analysis suggests that placental  
295 mitochondria are involved in the development of pre-eclampsia. *PloS one*. 2013;8(5):e64351. Epub  
296 2013/05/15. doi: 10.1371/journal.pone.0064351. PubMed PMID: 23671712; PubMed Central PMCID:  
297 PMCPMC3650054.
- 298 27. Harman D. The biologic clock: the mitochondria? *Journal of the American Geriatrics Society*.  
299 1972;20(4):145-7. Epub 1972/04/01. doi: 10.1111/j.1532-5415.1972.tb00787.x. PubMed PMID: 5016631.
- 300 28. Stefanatos R, Sanz A. The role of mitochondrial ROS in the aging brain. *FEBS letters*. 2018;592(5):743-  
301 58. Epub 2017/11/07. doi: 10.1002/1873-3468.12902. PubMed PMID: 29106705.
- 302 29. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. Reanalysis and revision  
303 of the Cambridge reference sequence for human mitochondrial DNA. *Nature genetics*. 1999;23(2):147. Epub  
304 1999/10/03. doi: 10.1038/13779. PubMed PMID: 10508508.

- 305 30. Tuppen HA, Blakely EL, Turnbull DM, Taylor RW. Mitochondrial DNA mutations and human disease.  
306 *Biochimica et biophysica acta*. 2010;1797(2):113-28. Epub 2009/09/19. doi: 10.1016/j.bbabbio.2009.09.005.  
307 PubMed PMID: 19761752.
- 308 31. Howell N, Elson JL, Turnbull DM, Herrnstadt C. African Haplogroup L mtDNA sequences show violations  
309 of clock-like evolution. *Molecular biology and evolution*. 2004;21(10):1843-54. Epub 2004/06/11. doi:  
310 10.1093/molbev/msh184. PubMed PMID: 15190127.
- 311 32. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. *Annual review of*  
312 *pathology*. 2010;5:297-348. Epub 2010/01/19. doi: 10.1146/annurev.pathol.4.110807.092314. PubMed PMID:  
313 20078222; PubMed Central PMCID: PMCPMC3245719.
- 314 33. Chinnery PF, Gomez-Duran A. Oldies but Goldies mtDNA Population Variants and Neurodegenerative  
315 Diseases. *Frontiers in neuroscience*. 2018;12:682. Epub 2018/10/30. doi: 10.3389/fnins.2018.00682. PubMed  
316 PMID: 30369864; PubMed Central PMCID: PMCPMC6194173.
- 317 34. Salas A, Elson JL. Mitochondrial DNA as a risk factor for false positives in case-control association  
318 studies. *Journal of genetics and genomics = Yi chuan xue bao*. 2015;42(4):169-72. Epub 2015/05/09. doi:  
319 10.1016/j.jgg.2015.03.002. PubMed PMID: 25953355.
- 320 35. Torbergesen T, Oian P, Mathiesen E, Borud O. Pre-eclampsia--a mitochondrial disease? *Acta obstetricia*  
321 *et gynecologica Scandinavica*. 1989;68(2):145-8. Epub 1989/01/01. doi: 10.3109/00016348909009902.  
322 PubMed PMID: 2589041.
- 323 36. Widschwendter M, Schrocksnadel H, Mortl MG. Pre-eclampsia: a disorder of placental mitochondria?  
324 *Molecular medicine today*. 1998;4(7):286-91. Epub 1998/09/23. doi: 10.1016/s1357-4310(98)01293-3. PubMed  
325 PMID: 9743989.
- 326 37. Teran E, Hernandez I, Tana L, Teran S, Galaviz-Hernandez C, Sosa-Macias M, et al. Mitochondria and  
327 Coenzyme Q10 in the Pathogenesis of Preeclampsia. *Frontiers in physiology*. 2018;9:1561. Epub 2018/12/01.  
328 doi: 10.3389/fphys.2018.01561. PubMed PMID: 30498451; PubMed Central PMCID: PMCPMC6249996.
- 329 38. Bybjerg-Grauholm J, Hagen CM, Gonçalves VF, Bækvad-Hansen M, Hansen CS, Hedley PL, et al.  
330 Complex spatio-temporal distribution and genogeographic affinity of mitochondrial DNA haplogroups in 24,216  
331 Danes. *bioRxiv*. 2017:148494.
- 332 39. Martinez-Redondo D, Marcuello A, Casajus JA, Ara I, Dahmani Y, Montoya J, et al. Human mitochondrial  
333 haplogroup H: the highest VO<sub>2</sub>max consumer--is it a paradox? *Mitochondrion*. 2010;10(2):102-7. Epub  
334 2009/11/11. doi: 10.1016/j.mito.2009.11.005. PubMed PMID: 19900587.
- 335 40. Gomez-Duran A, Pacheu-Grau D, Lopez-Gallardo E, Diez-Sanchez C, Montoya J, Lopez-Perez MJ, et al.  
336 Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups.  
337 *Hum Mol Genet*. 2010;19(17):3343-53. Epub 2010/06/23. doi: 10.1093/hmg/ddq246. PubMed PMID:  
338 20566709.
- 339 41. Stefano E, Marsigliante S, Vetrugno C, Muscella A. Is mitochondrial DNA profiling predictive for athletic  
340 performance? *Mitochondrion*. 2019;47:125-38. Epub 2019/06/23. doi: 10.1016/j.mito.2019.06.004. PubMed  
341 PMID: 31228565.
- 342 42. Hagen CM, Aidt FH, Hedley PL, Jensen MK, Havndrup O, Kanters JK, et al. Mitochondrial haplogroups  
343 modify the risk of developing hypertrophic cardiomyopathy in a Danish population. *PLoS One*.  
344 2013;8(8):e71904. Epub 2013/08/14. doi: 10.1371/journal.pone.0071904. PubMed PMID: 23940792; PubMed  
345 Central PMCID: PMCPMC3734310.
- 346 43. Amo T, Yadava N, Oh R, Nicholls DG, Brand MD. Experimental assessment of bioenergetic differences  
347 caused by the common European mitochondrial DNA haplogroups H and T. *Gene*. 2008;411(1-2):69-76. Epub  
348 2008/02/19. doi: 10.1016/j.gene.2008.01.007. PubMed PMID: 18280061; PubMed Central PMCID:  
349 PMCPMC2270349.

- 350 44. Baudouin SV, Saunders D, Tiangyou W, Elson JL, Poynter J, Pyle A, et al. Mitochondrial DNA and survival  
351 after sepsis: a prospective study. *Lancet (London, England)*. 2005;366(9503):2118-21. Epub 2005/12/20. doi:  
352 10.1016/S0140-6736(05)67890-7. PubMed PMID: 16360789.
- 353 45. Wojdemann KR, Shalmi AC, Christiansen M, Larsen SO, Sundberg K, Brocks V, et al. Improved first-  
354 trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of  
355 9941 low-risk women. *Ultrasound Obstet Gynecol*. 2005;25(3):227-33. doi: 10.1002/uog.1834. PubMed PMID:  
356 15736185.
- 357 46. De Villiers CP, Hedley PL, Placing S, Wøjdemann KR, Shalmi A-C, Carlsen AL, et al. Placental protein-13  
358 (PP13) in combination with PAPP-A and free leptin index (fLI) in first trimester maternal serum screening for  
359 severe and early preeclampsia. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2018;56(1):65-74.
- 360 47. Hedley PL, Placing S, Wojdemann K, Carlsen AL, Shalmi AC, Sundberg K, et al. Free leptin index and  
361 PAPP-A: a first trimester maternal serum screening test for pre-eclampsia. *Prenatal Diag*. 2010;30(2):103-9. doi:  
362 10.1002/pd.2337. PubMed PMID: 20013873.
- 363 48. Christiansen M, Hedley PL, Placing S, Wøjdemann KR, Carlsen AL, Jørgensen JM, et al. Maternal serum  
364 resistin is reduced in first trimester preeclampsia pregnancies and is a marker of clinical severity. *Hypertension*  
365 *in pregnancy*. 2015;34(4):422-33.
- 366 49. Laigaard J, Sørensen T, Placing S, Holck P, Fröhlich C, Wøjdemann KR, et al. Reduction of the disintegrin  
367 and metalloprotease ADAM12 in preeclampsia. *Obstetrics & Gynecology*. 2005;106(1):144-9.
- 368 50. Benn M, Schwartz M, Nordestgaard BG, Tybjaerg-Hansen A. Mitochondrial haplogroups: ischemic  
369 cardiovascular disease, other diseases, mortality, and longevity in the general population. *Circulation*.  
370 2008;117(19):2492-501. Epub 2008/05/07. doi: 10.1161/CIRCULATIONAHA.107.756809. PubMed PMID:  
371 18458168.
- 372 51. DSOG. Hypertension og præeklamsi 2018 [cited 2022 22-04-2022]. Available from: [www.dsog.dk](http://www.dsog.dk).
- 373 52. Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonak J, Lind K, et al. The real-time polymerase chain  
374 reaction. *Molecular aspects of medicine*. 2006;27(2-3):95-125. Epub 2006/02/08. doi:  
375 10.1016/j.mam.2005.12.007. PubMed PMID: 16460794.
- 376 53. Elson JL, Lightowlers RN. Mitochondrial DNA clonality in the dock: can surveillance swing the case?  
377 *Trends in genetics : TIG*. 2006;22(11):603-7. Epub 2006/09/19. doi: 10.1016/j.tig.2006.09.004. PubMed PMID:  
378 16979783.
- 379 54. Venter M, Tomas C, Pienaar IS, Strassheim V, Erasmus E, Ng WF, et al. MtDNA population variation in  
380 Myalgic encephalomyelitis/Chronic fatigue syndrome in two populations: a study of mildly deleterious variants.  
381 *Sci Rep*. 2019;9(1):2914. Epub 2019/03/01. doi: 10.1038/s41598-019-39060-1. PubMed PMID: 30814539;  
382 PubMed Central PMCID: PMC6393470.
- 383 55. Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? *BJOG : an international journal of*  
384 *obstetrics and gynaecology*. 2004;111(4):298-302. Epub 2004/03/11. doi: 10.1111/j.1471-0528.2004.00071.x.  
385 PubMed PMID: 15008762.
- 386 56. Redman CWG, Staff AC, Roberts JM. Syncytiotrophoblast stress in preeclampsia: the convergence point  
387 for multiple pathways. *American journal of obstetrics and gynecology*. 2022;226(2S):S907-S27. Epub 20210202.  
388 doi: 10.1016/j.ajog.2020.09.047. PubMed PMID: 33546842.
- 389 57. Hagen CM, Gonçalves VF, Hedley PL, Bybjerg-Grauholm J, Bækvad-Hansen M, Hansen CS, et al.  
390 Schizophrenia-associated mt-DNA SNPs exhibit highly variable haplogroup affiliation and nuclear ancestry: Bi-  
391 genomic dependence raises major concerns for link to disease. *PloS one*. 2018;13(12):e0208828.
- 392 58. Janssen BG, Munters E, Pieters N, Smeets K, Cox B, Cuypers A, et al. Placental mitochondrial DNA  
393 content and particulate air pollution during in utero life. *Environmental health perspectives*. 2012;120(9):1346-  
394 52. Epub 2012/05/26. doi: 10.1289/ehp.1104458. PubMed PMID: 22626541; PubMed Central PMCID:  
395 PMC3440109.

- 396 59. Bouhours-Nouet N, May-Panloup P, Coutant R, de Casson FB, Descamps P, Douay O, et al. Maternal  
397 smoking is associated with mitochondrial DNA depletion and respiratory chain complex III deficiency in  
398 placenta. *American journal of physiology Endocrinology and metabolism*. 2005;288(1):E171-7. Epub  
399 2004/12/09. doi: 10.1152/ajpendo.00260.2003. PubMed PMID: 15585597.
- 400 60. Busnelli A, Lattuada D, Ferrari S, Reschini M, Colciaghi B, Somigliana E, et al. Mitochondrial DNA Copy  
401 Number in Peripheral Blood in the First Trimester of Pregnancy and Different Preeclampsia Clinical Phenotypes  
402 Development: A Pilot Study. *Reproductive sciences (Thousand Oaks, Calif)*. 2019;26(8):1054-61. Epub  
403 2018/10/10. doi: 10.1177/1933719118804410. PubMed PMID: 30296910.
- 404 61. Qiu C, Hevner K, Enquobahrie DA, Williams MA. A case-control study of maternal blood mitochondrial  
405 DNA copy number and preeclampsia risk. *International journal of molecular epidemiology and genetics*.  
406 2012;3(3):237-44. Epub 2012/10/11. PubMed PMID: 23050054; PubMed Central PMCID: PMC3459217.  
407  
408

409 Table 1. Clinical and demographic data of the preeclampsia (PE) cases and pregnancy controls.  
 410 ‘Control’ is the group of healthy pregnancies. ‘PE’ is the preeclampsia patients. †Severity refers to the  
 411 severity of PE (PE 1=uncomplicated PE, PE 2=severe PE, PE 3=HELLP syndrome). Parity refers to the  
 412 number of times the woman has given birth.

	<b>Pregnancy control</b>	<b>All PE</b>	<b>Severity</b>		
			<b>PE 1</b>	<b>PE 2</b>	<b>PE 3 (HELLP)</b>
<b>Number of Individuals</b>	235	78	61	14	3
<b>Maternal Age*</b> (years)	30.2 (4.3)	30.3 (4.9)	30.5 (5.2)	30.2 (3.4)	29.3 (3.7)
<b>Maternal Weight*</b> (kg)	64.3 (19)	69.5 (11.6)	68.3 (11.8)	73.4 (10.9)	69 (8.3)
<b>Parity:</b>					
0	55.7 %	61.0 %	60.7 %	64.3 %	66.7 %
1	26.1 %	24.4 %	24.6 %	28.6 %	0.0 %
≥2	18.3 %	14.1 %	14.8 %	7.1 %	33.3 %
<b>Gestational Age at birth</b> (days)	283.1 (8)	273.9 (15.6)	277.5 (11.7)	263.6 (21.3)	249.7 (9.9)
<b>Birth Weight</b> (g)	3591 (447.2)	3192 (729.4)	3293 (606.3)	2999 (945.7)	2045 (699.6)

413

414

415 Table 2. Haplogroup distribution for preeclampsia (PE) pregnancies, control pregnancies and the  
 416 general population controls from Benn et al. 2008.

<b>Haplogroup</b>	<b>PE (%)</b>	<b>Pregnancy Control (%)</b>	<b>Population Control (%)</b>
<b>A</b>	0	2 (0.85)	n.d.
<b>B</b>	0	1 (0.4)	n.d.
<b>C</b>	0	1 (0.4)	n.d.
<b>H</b>	38 (48.7)	105 (44.7)	4244 (45.9)
<b>HV</b>	0	5 (2.1)	412† (4.5)
<b>I</b>	2 (2.6)	9 (3.9)	350* (3.8)
<b>J</b>	5 (6.4)	16 (6.8)	843 (9.1)
<b>K</b>	5 (6.4)	20 (8.5)	571 (6.2)
<b>L</b>	1 (1.3)	1 (0.4)	n.d.
<b>N</b>	1 (1.3)	4 (1.7)	n.d.
<b>R</b>	0	1 (0.4)	n.d.
<b>T</b>	10 (12.8)	18 (7.6)	912 (9.9)
<b>U</b>	11 (14.1)	35 (14.9)	35 (14.9)
<b>V</b>	4 (1.7)	9 (3.8)	412† (4.5)
<b>W</b>	0	1 (0.4)	n.d.
<b>X</b>	0	1 (0.4)	n.d.
<b>Z</b>	0	1 (0.4)	324 (3.5)
<b>W/I</b>	2 (2.6)	10 (4.3)	350* (3.8)
<b>NA</b>	1 (1.3)	5 (2.1)	n.d.
<b>Total</b>	78 (100)	235 (100)	9254 (100)

417 \* Haplogroup was not distinguished. † haplogroup HV and V were not distinguished. NA not available. n.d. not  
 418 determined.

419 Table 3. Comparison of the haplogroup distribution in the healthy pregnancy control group and a  
420 general Danish population. It shows that there were no significant differences ( $p$ -value  $> 0.05$ ), it can  
421 be concluded that the healthy pregnancy control group is representative for the general Danish  
422 population.

Test setup	Pregnancy control/ population control, percentage	Fisher's exact test, p-value	Odds-ratio	95% CI
<b>H vs. non-H</b>	44.5/46.6	0.55	1.08	0.82-1.43
<b>U vs. non-U</b>	14.9/15.9	0.65	1.09	0.76-1.6
<b>K vs. non-K</b>	8.5/6.2	0.21	0.72	0.42-1.23
<b>J vs. non-J</b>	6.8/9.1	0.13	1.54	0.9-2.82
<b>T vs. non-T</b>	7.6/9.9	0.49	1.23	0.75-2.14
<b>V vs. non-V</b>	3.8/4.5	0.79	0.63	0.63-2.79



423 Table 4. Comparison of preeclamptic pregnancies and healthy control pregnancies for each haplogroup.

Test setup	PE/ pregnancy control, percentage	Fisher's exact test, p-value	Odds-ratio	95% CI
<b>H vs. non-H</b>	49/44	0.6	1.19	0.68-2
<b>U vs. non-U</b>	14/15	1	0.9	0.4-2
<b>K vs. non-K</b>	6/8	0.64	0.73	0.2-2.1
<b>J vs. non-J</b>	6/7	1	0.93	0.26-2.8
<b>T vs. non-T</b>	13/8	0.17	1.78	0.7-4.29
<b>I vs. non-I</b>	3/4	1	0.7	0.06-3.3
<b>V vs. non-V</b>	5/4	0.74	1.4	0.3-5
<b>L vs. non-L</b>	1/0.5	0.44	3	0.38-240
<b>N vs. non-N</b>	1/2	1	0.75	0.15-7.76


424 CI: confidence interval

425 Table 5. Comparison of preeclamptic pregnancies and a general population control from Benn et al  
426 2008 for each haplogroup.

Test setup	PE/ Population control, percentage	Fisher's exact test, p-value	Odds-ratio	95% CI
<b>H vs. non-H</b>	49/46,6	0.73	1.09	0.67-1.74
<b>U vs. non-U</b>	14/15.9	0.64	0.83	0.4-1.6
<b>K vs. non-K</b>	6/6.2	1	1.01	0.3-2.5
<b>J vs. non-J</b>	6/9.1	0.44	1.44	0.66-2.85
<b>T vs. non-T</b>	13/9.9	0.32	1.78	0.7-4.29
<b>V vs. non-V</b>	5/4.5	0.79	1.09	0.3-3

427 CI: confidence interval

428 Figure 1



429

430 Figure 1. Haplogroup distribution and severity of PE. The x-axis shows the haplogroups, while the y-  
431 axis is the number of PE patients. PE 1 is the mildest, uncomplicated form of preeclampsia (PE 1  
432 n=61). PE 2 is severe preeclampsia (PE 2 n=14). PE 3 is preeclampsia complicated with HELLP  
433 syndrome (PE 3 n=3). NA is the individuals with an unknown haplogroup.

434